This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Order Print Publication
You May Also Be Interested In
This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.
This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.
This brochure informs patients about buprenorphine and medication-assisted treatment for opioid use disorder. It describes addiction and withdrawal, how buprenorphine works, its proper use, its side effects, and how it fits with counseling in the recovery process.
This brochure describes the use of methadone in medication-assisted treatment of heroin and other opioids, including narcotic pain medicines. It describes how to use methadone safely, the dangers of methadone overdose, and life-threatening methadone side effects.
This poster lists five simple ways to reduce the risks of taking methadone for pain relief or medication-assisted treatment of opioid use disorders. It also offers suggested resources for additional information. The poster comes folded and is 11 inches x 15 inches.
Pharmacologic Guidelines for Treating Individuals with Post-Traumatic Stress Disorder and Co-Occurring Opioid Use Disorders
This manual offers guidelines for medication-assisted treatment for people, particularly veterans, living with post-traumatic stress disorder and co-occurring opioid use disorders. It covers screening, concomitant treatment, pharmacotherapy, and multiple misused substances.